These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1661 related items for PubMed ID: 31326413

  • 1. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P.
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [Abstract] [Full Text] [Related]

  • 2. Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
    Wang C, Gu Y, Chu Q, Wang X, Ding Y, Qin X, Liu T, Wang S, Liu X, Wang B, Cao H.
    Microbiol Res; 2024 May; 282():127660. PubMed ID: 38442454
    [Abstract] [Full Text] [Related]

  • 3. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy.
    Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, Coufal S, Thon T, Mihula M, Modrak M, Kverka M, Bajer L, Kostovcikova K, Drastich P, Hercogova J, Novakova M, Vasatko M, Lukas M, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z.
    Cells; 2021 Nov 16; 10(11):. PubMed ID: 34831411
    [Abstract] [Full Text] [Related]

  • 4. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.
    Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Lin E, Borody TJ, Wilkins MR, Colombel JF, Mitchell HM, Kaakoush NO.
    Gastroenterology; 2019 Apr 16; 156(5):1440-1454.e2. PubMed ID: 30529583
    [Abstract] [Full Text] [Related]

  • 5. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, Nice R, Lin S, Prabhudev H, Sands C, Horneffer-van der Sluis V, Lewis M, Sebastian S, Lees CW, Teare JP, Hart A, Goodhand JR, Kennedy NA, Korcsmaros T, Marchesi JR, Ahmad T, Powell N.
    EBioMedicine; 2023 Feb 16; 88():104430. PubMed ID: 36634565
    [Abstract] [Full Text] [Related]

  • 6. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients.
    Alatawi H, Mosli M, Saadah OI, Annese V, Al-Hindi R, Alatawy M, Al-Amrah H, Alshehri D, Bahieldin A, Edris S.
    Bosn J Basic Med Sci; 2022 Jun 01; 22(3):412-426. PubMed ID: 34761733
    [Abstract] [Full Text] [Related]

  • 7. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.
    Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A, Ellul P.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0061622. PubMed ID: 35532243
    [Abstract] [Full Text] [Related]

  • 8. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients.
    Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K, Tilg H.
    J Crohns Colitis; 2021 Jan 13; 15(1):88-98. PubMed ID: 32687146
    [Abstract] [Full Text] [Related]

  • 9. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    J Gastroenterol Hepatol; 2019 Dec 13; 34(12):2090-2095. PubMed ID: 31169926
    [Abstract] [Full Text] [Related]

  • 10. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S.
    Clin Gastroenterol Hepatol; 2018 May 13; 16(5):697-705.e7. PubMed ID: 29223444
    [Abstract] [Full Text] [Related]

  • 11. Correlation of diet, microbiota and metabolite networks in inflammatory bowel disease.
    Weng YJ, Gan HY, Li X, Huang Y, Li ZC, Deng HM, Chen SZ, Zhou Y, Wang LS, Han YP, Tan YF, Song YJ, Du ZM, Liu YY, Wang Y, Qin N, Bai Y, Yang RF, Bi YJ, Zhi FC.
    J Dig Dis; 2019 Sep 13; 20(9):447-459. PubMed ID: 31240835
    [Abstract] [Full Text] [Related]

  • 12. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B, Le CRI.
    Joint Bone Spine; 2012 Oct 13; 79(5):457-63. PubMed ID: 22088934
    [Abstract] [Full Text] [Related]

  • 13. Dynamic Colonization of Microbes and Their Functions after Fecal Microbiota Transplantation for Inflammatory Bowel Disease.
    Chu ND, Crothers JW, Nguyen LTT, Kearney SM, Smith MB, Kassam Z, Collins C, Xavier R, Moses PL, Alm EJ.
    mBio; 2021 Aug 31; 12(4):e0097521. PubMed ID: 34281401
    [Abstract] [Full Text] [Related]

  • 14. Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.
    Caenepeel C, Falony G, Machiels K, Verstockt B, Goncalves PJ, Ferrante M, Sabino J, Raes J, Vieira-Silva S, Vermeire S.
    Gastroenterology; 2024 Mar 31; 166(3):483-495. PubMed ID: 38096956
    [Abstract] [Full Text] [Related]

  • 15. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
    Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD.
    mBio; 2018 Mar 13; 9(2):. PubMed ID: 29535202
    [Abstract] [Full Text] [Related]

  • 16. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M, Nikolac Gabaj N, Ćelap I, Grazio S, Tomašić V, Bišćanin A, Mitrović J, Đerek L, Morović-Vergles J, Vrkić N, Štefanović M.
    Rheumatol Int; 2021 Dec 13; 41(12):2195-2203. PubMed ID: 34623480
    [Abstract] [Full Text] [Related]

  • 17. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
    Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, Rehman A, Tran F, Aden K, Häsler R, Moll N, Schütze G, Schwarz MJ, Waetzig GH, Rosenstiel P, Krawczak M, Szymczak S, Schreiber S.
    Gastroenterology; 2017 Dec 13; 153(6):1504-1516.e2. PubMed ID: 28827067
    [Abstract] [Full Text] [Related]

  • 18. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.
    Wang ZK, Yang YS, Chen Y, Yuan J, Sun G, Peng LH.
    World J Gastroenterol; 2014 Oct 28; 20(40):14805-20. PubMed ID: 25356041
    [Abstract] [Full Text] [Related]

  • 19. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
    Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL.
    J Crohns Colitis; 2020 Sep 07; 14(8):1090-1102. PubMed ID: 32119090
    [Abstract] [Full Text] [Related]

  • 20. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
    Babickova J, Gardlik R.
    World J Gastroenterol; 2015 Oct 28; 21(40):11321-30. PubMed ID: 26525290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.